Hepion Pharmaceuticals acquires Gravitas Life Sciences in cash-and-stock deal

Bitget2026/10/09 20:31

Hepion Pharmaceuticals acquired Gravitas Life Sciences on Oct. 6, 2026, buying all outstanding membership interests from Gravitas Collective. Consideration: USD 2 million cash, 25,000,000 common shares, subject to a 19.99% issuance cap with any shortfall settled in cash. An additional USD 135,000 cash payment was made to the seller at closing. USD 1 million was paid to Canton Strategic Holdings, with USD 125,000 paid by Gravitas Life Sciences as a mandatory prepayment on a promissory note. The remaining Canton note obligations were assigned to Hepion, which became sole maker, obligor, and guarantor. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hepion Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-046546), on October 09, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.